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Esophageal squamous cell carcinoma and esophageal adenocarcinoma are cancers of
high mortality. EAC develops through Barrett’s esophagus (BE) and columnar dysplasia,
preceded by gastro-esophageal reflux disease. The risk of esophageal squamous cell car-
cinoma is increased by smoking and alcohol consumption. New treatment options for
esophageal cancer are desperately needed. Toll-like receptors (TLRs) play a central role
in mammalian immunity and cancer. TLRs are activated by microbial components, such
as lipopolysaccharide, flagellin, DNA, and RNA, as well as endogenous ligands, including
heat-shock proteins and endogenous DNA. This review summarizes the studies on TLRs
in esophageal squamous cell carcinoma and EAC. It has been shown that TLRs 1–10 are
expressed in the normal esophagus. In esophageal squamous cell carcinoma, TLRs3, 4, 7,
and 9 have been studied, showing associations to aggressive disease properties. In BE and
EAC, only TLRs4, 5, and 9 have been studied. In the review, we discuss the implications
of TLRs in esophageal cancer.
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INTRODUCTION
Toll-like receptors (TLRs) are evolutionarily conserved recep-
tors of the innate immune system (1). The 13 TLRs that have
been identified so far recognize their unique pathogen-associated
molecular patterns (PAMPs), such as bacterial lipopolysaccha-
ride (LPS) (TLR4), DNA (TLR9), or flagellin (TLR5) (1, 2). TLR
stimulation induces down-stream activation of various signal-
ing molecules and this ultimately results in the innate immune
response, which also activates the adaptive immune system (1–
3). The aim of this review is to explore the role and function of
TLRs in esophageal adenocarcinoma (EAC) and in squamous cell
carcinoma.
ESOPHAGEAL CANCER
Esophageal cancer is the eighth most common cancer in the
world with estimated 482,000 new cases worldwide in 2008. The
incidence of esophageal cancer was 70/100,000 in 2008 in the
world. The majority of esophageal cancers are esophageal squa-
mous cell carcinomas (ESCC), but the incidence of EAC is rising
rapidly (4, 5).
As with oral squamous cell cancer, tobacco and alcohol, low
socioeconomic status, poor oral health, and betel nuts, as well
as the autoimmune polyendocrinopathy–candidiasis–ectodermal
dystrophy (APECED)-syndrome have been listed as risk factors
for ESCC (6–10). With regard to pathologic anatomy, esophagus
could be considered as an extension of the oral cavity, as it is lined
by squamous epithelium and it encounters swallowed oral bacteria
before they enter the stomach.
For EAC, the most important risk factor is Barrett’s esophagus
(BE), determined by columnar metaplastic cells, which replace the
normal squamous epithelium after long-lasting gastro-esophageal
reflux, or gastro-esophageal reflux disease (GERD). Patients with
BE have a 30- to 125-fold risk for EAC compared to normal popu-
lation (11, 12). A recent study, however, concluded that only 0.12%
of patients with BE develop EAC (13). Other minor risk factors
include obesity, smoking, hiatal hernia, and low socioeconomic
status (10, 14–18). Furthermore, both types of esophageal cancers
develop through dysplasia to cancer via genetic alterations (19, 20).
The 5-year survival rate for esophageal cancer varies between
10 and 16% (4). After esophageal resection, the 5-year survival rate
was 20.6% in a meta-analysis of Western population (21). Further-
more, these cancers are often diagnosed late because at the time of
the diagnosis, more than half of the patients have an inoperable
disease (22).
The most important prognostic determinant for both
esophageal cancers is the WHO TNM-classification (23). The his-
tologically defined grade of differentiation is also a predictor of
prognosis (24).
TOLL-LIKE RECEPTORS IN NORMAL ESOPHAGUS
Esophageal epithelial cells have been shown to express TLRs. The
human esophageal epithelial cell-line TE-1 was shown to express
TLRs2, 3, 4, and 7, with up-regulation of beta-defensin 2 as a
response to stimulation with their cognate, synthetic ligands (25).
In 2009, Lim and colleagues demonstrated the expression of TLRs
1–10, but not TLR4 at the mRNA level in the normal human
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esophageal epithelial cell-line EPC-2. Furthermore, they demon-
strated TLR1, 2, 3, and 5 mRNA expression in biopsies taken from
esophageal mucosa. IL-8 was up-regulated in the EPC-2 cells by
stimulation of the respective TLR-ligands. TLR3 stimulation was
the most effective in inducing IL-8 expression synergistically with
TLR2 and this effect was dependent on NF-kB activation (26).
TLR3 was later demonstrated also to mediate the induction
of IL-8 mRNA via NF-kB by necrotic cell supernatants in the
EPC-2 cells (27). TLR2 and TLR3 protein expression was demon-
strated in esophageal epithelial cells, but not in cultured primary
esophageal epithelial cells (28). The expression of TLR3, 4, 5, 7,
and 9 proteins in normal esophagus has been characterized using
immunohistochemistry in clinical samples (29–31). These stud-
ies have demonstrated that TLRs 1–10 are expressed in normal
esophagus.
TOLL-LIKE RECEPTORS AND ESOPHAGEAL SQUAMOUS CELL
CARCINOMA
Esophageal squamous cell carcinoma develops to squamous
epithelium via dysplasia. A variety of TLRs, including TLR3, 4,
7, and 9, have been shown to be overexpressed in esophageal squa-
mous cell carcinoma, when compared to normal esophagus (30,
31). We demonstrated an increased TLR9 expression in esophageal
squamous dysplasia and in squamous cell carcinoma, suggesting a
possible role for TLR9 in esophageal carcinogenesis (31).
High TLR3, 4, and 9 expression in esophageal squamous cell
carcinoma cells have been associated with lymph node metasta-
sis and TLR7 and 9 expression to worse histological grade (30,
31). TLR9 expression in the fibroblastoid cells of the tumor was,
however, associated with decreased invasion depth and a smaller
prevalence of lymph node metastasis at the time of diagnosis (30).
TLR4 stimulation by LPS has been shown to increase migration
and adhesive properties of esophageal squamous cell carcinoma
cells via p38 and selectin (32). No studies thus far have evalu-
ated the anti-cancer efficacy of TLR-agonists or inhibitors in the
treatment of ESCC.
TOLL-LIKE RECEPTORS, BARRETT’S ESOPHAGUS, AND
ESOPHAGEAL ADENOCARCINOMA
Esophageal adenocarcinoma is developed through the metaplasia–
dysplasia–carcinoma sequence. Normal or inflamed esophageal
epithelium is believed to transform to BE or columnar metaplasia
through continuous exposure to acidic gastric contents, but also
transformation of esophageal microbiome occurs during these
changes (33, 34).
It was shown in BE and in normal human esophageal cell
lines, that stimulation of TLR4 with LPS resulted in NF-κB acti-
vation and an increase of IL-8 secretion, this response was more
significant in BE. Ex vivo culture demonstrated increased cyclo-
oxygenase-2 (COX-2) activation by LPS stimulation of TLR4 in
BE (35). TLR5 was recently analyzed in the metaplasia–dysplasia–
adenocarcinoma sequence, with high expression potentially dif-
ferentiating between BE and columnar dysplasia (29).
The increased expression of TLR5 and 9 has been shown in
EAC. TLR5 expression had no associations to clinico-pathological
variables or prognosis, but TLR9 expression was associated with
metastasis, poor grade of differentiation and poor prognosis in
EAC (29, 36). Stimulation of EAC cells with CpG-oligonucleotides
that either have the physiological phosphodiester DNA-backbone
or the nuclease-resistant phosphothioate backbone, induced cel-
lular invasion and matrix metalloproteinase-9 and -13 mRNA
expression (37).
At the current moment, there are no published clinical studies
on TLRs in EAC.
TOLL-LIKE RECEPTOR GENETICS AND ESOPHAGEAL CANCER
Genetic studies have been performed on Toll-like receptor poly-
morphisms in esophageal cancer. Unlike in gastric cancer, poly-
morphisms in TLR4+ 896A>G and TLR9-1237T/C genes were
not associated to esophageal cancer risk (38, 39). However, genetic
up-regulation of CD14, a co-receptor of TLR4, was observed in
families with history of esophageal cancer (40).
DISCUSSION
The treatment of esophageal cancer is overshadowed by its poor
prognosis. New options for early diagnosis and treatment are des-
perately needed. The esophageal epithelium encounters bacteria
from oral cavity and in the case of reflux disease, also from the
stomach and possibly also from the duodenum. TLRs act by rec-
ognizing bacteria-derived molecular patterns which results in a
pro-inflammatory reaction in the epithelium.
The role of TLRs in esophageal cancer has been studied sparsely.
However, there is evidence that the function of TLRs is pro-
carcinogenic and pro-inflammatory as the overexpression of many
of the TLRs have been linked with esophageal cancer and with
poor prognosis. Inflammation is a known important factor in
the pathogenesis of various cancers. It was demonstrated by Yang
et al. that the microbiome of distal esophagus frequently under-
goes changes during esophagitis and BE. During these processes,
the microbiome is switched from aerobic to gram-negative anaer-
obic bacteria (33, 34). This finding together with abnormal TLR
expression, particularly those of TLRs4, 5, and 9, in esophageal
cancer supports the hypothesis of bacteria contributing to the car-
cinogenesis of esophageal cancer. These findings further suggest
that TLRs may be important mediators for bacteria in oncogenesis
(37, 40, 41).
In addition to microbes, TLRs can also detect molecular pat-
terns that are derived from the host itself. TLRs3, 4, and 9 are
known to be activated by endogenous ligands from dead or dam-
aged host cells (42, 43). The combination of cellular damage by
alcohol, tobacco, and acidic contents of the stomach results in
the loss of epithelial wall integrity, through epithelial cell death
and by disruption of the cell-to-cell contacts. Especially TLR3 and
TLR9 (but also other TLRs) can recognize particles from dead
cells (43). This can result in an inflammatory wound reaction
through the activation of interleukins, NF-kB, and matrix metal-
loproteinases. This wound reaction could facilitate the passage
of bacteria through epithelium and result in the loss of host-
microbiome homeostasis, further leading to abnormal activation
of for example TLR2, 4, 5, and 9 by bacterial components. Inflam-
mation and wound reaction then could produce a vicious cycle
of cellular damage, which might be a major player in esophageal
metaplasia and carcinogenesis. This role of bacteria and TLR4
in genesis of BE has been discussed earlier by Yang et al. (33).
Cell-to-cell junctions become dysfunctional in exogenous damage
to the epithelium as discussed earlier. Thus, a similar effect can also
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FIGURE 1 |The proposed role ofToll-like receptors in esophageal cancer. Modified from Kauppila et al. (37).
be observed in dysplasia and cancer (44). This dysfunction may
lead to Toll-like receptor activation in cancer by exogenous and
endogenous ligands. The hypothesis is summarized in Figure 1.
Finally, Toll-like receptor expression is up-regulated in both
squamous cell carcinoma and adenocarcinoma of the esophagus.
This may indicate that cancer cells are sensitized to bacteria- and
host-derived ligands. Poor prognosis in strongly TLR-expressing
tumors could then be an indicator of increased level of tumor–
stroma interaction.
CONCLUSION
There seems to be a connection between TLRs and esophageal
cancer development. The fact that bacterial flora changes during
esophageal metaplasia and inflammation, as well as observed up-
regulation of TLRs in esophageal cancers support the hypothesis
that bacteria as well as TLRs have a role in esophageal cancer.
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